32results about How to "Reduce proliferation" patented technology

The invention provides a nanoparticle compound for inhibiting bone and soft tissue infection as well as a preparation method and application thereof, and belongs to the technical field of medical biological materials. The nanoparticle compound is a gentiopicroside, sericin, hyaluronic acid and endolysin liposome nanoparticle, and a gentiopicroside, sericin, hyaluronic acid and endolysin co-delivery nano drug delivery system targeting the S100A4 site is designed based on the target S100A4 closely related to bone infection through Ai molecular docking and nano drug delivery technologies. The nanoparticle compound provided by the invention has better stability and bioavailability, and can be used for improving and relieving inflammatory response and increasing wound healing effect.

The invention provides a culture method for improving immunity of fishes. The culture method comprises the following steps: S1, selection of culture points; S2, specification and layout of net cages; S3, selection and throwing of fish fries; according to the fry disinfection method disclosed by the invention, the fry are soaked and disinfected by using a compound disinfectant prepared from povidone iodine, polysorbate, citric acid and vitamin C in a specific proportion, so that pathogenic microorganisms on the surfaces and gill parts of fish bodies are effectively killed. According to the breeding management, the immunity of the fish body is comprehensively enhanced by feeding the fish with an immune conditioner composed of campesterol palmitate, immunomodulatory peptide, beta-glucan and astaxanthin in a specific proportion. According to the bottom mud management, the content of harmful substances is reduced by putting a bottom mud modifier composed of sodium molybdate, nitrifying bacteria, photosynthetic bacteria, tetrandrine and sodium alginate in a specific proportion, growth of pathogenic bacteria is inhibited, nutrient substance circulation is promoted, the water quality environment is optimized, and healthy growth of fry is promoted.

The invention relates to application of piRNA as a target spot in preparation of a medicine for treating lung cancer or lung injury caused by tobacco exposure, and belongs to the technical field of biomedicine. The invention provides application of piR-2850767 and / or piR-157618 as a target spot in preparation of a medicine for treating lung cancer or lung injury caused by tobacco exposure, and particularly relates to application of an expression inhibitor of piR-2850767 and / or an overexpression reagent of piR-157618 in preparation of a medicine for treating lung cancer or lung injury caused by tobacco exposure. The inhibitor and the overexpression preparation can cause growth inhibition of lung cancer representative cells A549 and cause apoptosis of the lung cancer representative cells A549, and can recover cell cycle arrest, cell apoptosis, cell proliferation and motor ability decline of lung epithelial cells caused by tobacco exposure as a preventive drug for lung injury caused by tobacco exposure.

The invention discloses a gene engineering exosome and a slow release method and application thereof, the gene engineering exosome is derived from human adipose-derived stem cells, si-tgfbr2 is loaded in the gene engineering exosome, the si-tgfbr2 is specific siRNA aiming at a Tgfbr2 gene, and the gene engineering exosome can regulate and control proliferation of VSMCs, inhibit transformation of the VSMCs from a contraction phenotype to a synthetic phenotype when the VSMCs are stimulated, and inhibit the growth of the VSMCs. According to the present invention, the gene engineering exosome can be used to maintain the normal structure and the function of the blood vessel, and the sustained release effect of the content in the gene engineering exosome can be achieved by wrapping the gene engineering exosome in the PHA biodegradable material, such that the local treatment concentration can be easily stabilized, the drug administration frequency can be easily reduced, the lasting time of the treatment effect can be easily prolonged, and the treatment gene can be effectively delivered to the target cell; the treatment effect is improved; when being used for modifying a small-caliber artificial blood vessel, the small-caliber artificial blood vessel can be improved in biocompatibility and functionality, and can be prevented from being implanted into the blood vessel for remodeling unbenign hyperplasia stenosis; the invention not only provides a new thought and method for the treatment of vascular diseases, but also has important clinical application value and popularization prospect.

The invention belongs to the technical field of biological medicines, and particularly relates to application of asparaginase in preparation of a medicine for treating pancreatic cancer. The asparaginase and the gemcitabine are combined for treating pancreatic cancer, and results show that the combination of the two medicines can promote apoptosis of pancreatic cancer cells, reduce proliferation and reduce activation of pancreatic stellate cells, so that an important scientific basis is provided for improving gemcitabine drug resistance, and meanwhile, a new application is provided for the asparaginase.

The invention belongs to the field of food, and particularly relates to application of a nutritional composition to auxiliary improvement of memory ability. The invention provides application of a nutritional composition in preparation of food which is taken by a mother to assist in improving memory ability of offspring. The nutritional composition comprises the following necessary components: active folic acid substances and N-acetylneuraminic acid, furthermore, in the nutritional composition, the mass ratio of the active folic acid substances to the N-acetylneuraminic acid is (0.0005 to 0.007) to (1 to 5); the mother comprises a mother in a gestation period and / or a mother in a lactation period, and the filial generation comprises a filial generation in a fetal period and / or a filial generation in an infant period and an optional filial generation in a child period. A large number of studies find that the composition of active folic acid substances and N-acetylneuraminic acid is supplemented to the pregnant mothers and / or the lactation mothers, and the positive effect can be achieved on the memory ability of the offspring.

The invention discloses an application of samidocardone in preparation of a medicine for treating pulmonary fibrosis. According to the application disclosed by the invention, the condition that the samidojun can inhibit the activity of the pulmonary fibrosis cells and reduce proliferation by inducing the ferroptosis of the pulmonary fibrosis cells is proposed and verified for the first time, and meanwhile, the expression of fibrosis-related proteins is reduced, so that the progress of the pulmonary fibrosis is effectively relieved, and a new direction is provided for treating the pulmonary fibrosis.

The present invention belongs to the technical field of biological preservatives, and specifically relates to a double-coated nanoemulsion of clove essential oil, which comprises clove essential oil, ε-polylysine, whey protein, lecithin, and corn starch. The present invention also provides a preparation method of the nanoemulsion and its use as a donkey meat preservative. The double-coated nanoemulsion of clove essential oil of the present invention not only retains the excellent properties of the original nanoemulsion, but also slows down the increase of pH value, the proliferation of microorganisms, and the oxidation of lipids and proteins to a certain extent, and greatly prolongs the shelf life.

The invention belongs to the field of diagnosis and molecular biology, and particularly relates to application and a method of a KRT17 gene in slowing down proliferation of pulmonary artery smooth muscle cells. According to the invention, high expression of KRT17 in PAH and hypoxia-induced PASMCs is found and proved, and proliferation of pulmonary artery smooth muscle cells can be slowed down by knocking out KRT17, so that a foundation is provided for subsequent development of KRT17 genes in cardiovascular diseases.

The invention belongs to the technical field of medicines, and particularly relates to application of NOTCH3 serving as a target spot to preparation of a pharmaceutical composition for treating bladder cancer. The invention relates to a targeted inhibitor of NOTCH3, which is shRNA (short hairpin ribonucleic acid). Experimental results show that NOTCH3 is a key oncogene of bladder cancer and can be used as a therapeutic target of bladder cancer, and an inhibitor of NOTCH3 can be used for preparing a pharmaceutical composition for treating bladder cancer.

The invention relates to the technical field of chemical medicines, in particular to application of a compound 2-(4-methanoyl) anilino-4-(1H-indole-4-oxy)-5-trifluoromethylpyrimidine in inhibition of the activity of Aurora and JAK kinase families and in treatment of several tumors. On the basis of the research of 2-(4-methanoyl) anilino-4-amino-5-trifluoromethylpyrimidine derivative and application (patent application number: 202110571344.8) in the early stage, the compound is found to be capable of inhibiting the activity of FAK kinase and effectively inhibiting the family activity of Aurora and JAK kinase, and the inhibition effects are respectively 100 times and 5 times or more superior to those of the FAK kinase, so that the compound can be used for preparing a novel compound for inhibiting the activity of the FAK kinase. The compound can be used as a dual-effect anti-tumor inhibitor and can reduce proliferation of breast cancer, lung cancer, leukemia, thyroid cancer, prostate cancer, glioma, ovarian cancer and lymphoma cells, the activity is not observed in other FAK kinase inhibitors (such as Defactinib), and the compound can be used as a dual-effect anti-tumor inhibitor. The compound is applied to preparation of medicines for treating breast cancer, lung cancer, leukemia, thyroid cancer, prostate cancer, glioma, ovarian cancer, lymphoma and idiopathic pulmonary fibrosis.

The present invention provides a use of NLN neurolysin in preparing a drug for preventing and treating lung cancer, and the present invention belongs to the field of medical science. It is first found that the level of NLN neurolysin in lung cancer tissue of lung cancer patients is significantly higher than that in adjacent cancer tissue. The present invention verifies that knocking out the NLN neurolysin gene can effectively prevent and treat lung cancer through gene knockout, and the present invention provides a target and treatment strategy for clinical treatment of lung cancer.

The invention discloses oligonucleotide mediating METTL3 variable splicing and application of the oligonucleotide in preparation of a medicine for treating hepatocellular carcinoma. The sequence of the oligonucleotide is any sequence as shown in SEQ ID No.1-7. According to the invention, the expression of the METTL3 splicing isomer is regulated in a targeted manner by using a specific ASO drug, the expression level of the METTL3-A splicing isomer for promoting cancer is reduced, and the expression level of the METTL3-D splicing isomer for inhibiting cancer is increased. The proliferation and clone formation capabilities of hepatoma cells with increased expression of METTL3-D splicing isomers are greatly reduced, and meanwhile, the invasion capability is also remarkably weakened. The expression of the METTL3-D splicing isomer is crucial to the inhibition of liver cancer cells. METTL3 variable splicing regulation provides a new target for clinical treatment of liver cancer, and has a remarkable clinical application prospect. The METTL3-ASO6 and the METTL3-ASO7 can be used for inhibiting the expression of the METTL3-A splicing isomer capable of promoting the cancer in liver cancer cells. The METTL3-ASO6 and the METTL3-ASO7 can be used for inhibiting the proliferation and the clone formation capability of liver cancer cells. The METTL3-ASO6 and the METTL3-ASO7 provided by the invention can be used for efficiently inhibiting the invasion ability of liver cancer cells.

This invention discloses the preparation and application of a bio-based active preservation film based on the synergistic utilization of multiple components of rice bran. Using defatted rice bran as the raw material, the invention employs bacterial cellulose obtained from the fermentation of defatted rice bran hydrolysate as the structural framework of the membrane matrix. Rice bran protein from the hydrolysis residue of defatted rice bran is prepared into nanoparticles, and a Pickering emulsion is formed by stabilizing thyme essential oil with these nanoparticles. Further, the defatted rice bran-based bacterial cellulose membrane is impregnated and modified with polyvinyl alcohol and glycerol. Then, the rice bran protein-stabilized thyme essential oil Pickering emulsion is coated onto the surface of the modified membrane matrix to obtain a bio-based active preservation film. The resulting preservation film can be used for the preservation and packaging of chilled meat, and can delay microbial proliferation, lipid oxidation, protein spoilage, and color deterioration during the storage of chilled meat.

The present invention belongs to the field of preparation of longan ginseng peptide probiotic powder, and particularly relates to a traditional Chinese medicine fermented longan ginseng peptide probiotic powder for treating tumors. Ginseng and American ginseng are crushed and powdered, vacuum concentrated to make ginseng peptide concentrate, and mixed with dried longan, artemisia annua, ashwagandha, knotweed, tripterygium wilfordii, cordyceps sinensis, and composite probiotic agents in a fermenter for full fermentation. The effective ingredient content is high and is conducive to absorption, while clearing away heat and promoting body fluid without toxic side effects; finally, the traditional Chinese medicine fermented longan ginseng peptide probiotic powder prepared by vacuum freeze drying has minimal biological activity damage, completely retains the active ingredients for treating tumors, and is convenient for long-term storage. After liver cancer mice take it, the tumor weight and volume are effectively suppressed, the liver function is less damaged, and the immune function of mice is protected, and the macrophage phagocytosis rate of mice reaches 79.6%.

Provided in the present invention is a pharmaceutical composition comprising hydroxyprogesterone caproate and an additional therapeutic agent for treating tumors, wherein the additional therapeutic agent is preferably a monoclonal antibody against PD-1 or PD-L1. Further provided in the present invention are a method for increasing the number of tumor infiltrating lymphocytes (TIL) as required and a method for treating cancers in a subject in need thereof, which comprises providing the hydroxyprogesterone caproate to the subject.

The application relates to the technical field of skin bacteriostatic liquid, and discloses a skin bacteriostatic liquid containing plant extracts and a preparation method thereof, which comprises the following raw materials in parts by mass: composite plant extracts containing nanocrystalline particles 15-20 parts, glycerol 3-4 parts, sodium hyaluronate 0.1-0.2 parts and purified water 75-85 parts. The composite plant extracts containing nanocrystalline particles, glycerol, sodium hyaluronate and purified water are mixed to obtain the skin bacteriostatic liquid, which has the advantages of strong bacteriostasis, long-acting bacteriostasis, mildness and no irritation, and can repair the skin barrier, realize long-acting skin bacteriostasis, reduce the repeated occurrence of skin inflammation, and relieve inflammatory skin aging.

The invention discloses application of microRNA (Ribonucleic Acid) as a diagnostic marker in an advanced colorectal cancer drug resistance diagnostic kit and application of microRNA in preparation of drugs for treating advanced colorectal cancer. The invention discovers that miR-196b-5p is highly expressed in a cetuximab-sensitive intestinal cancer cell line, and the expression quantity of miR-196b-5p in a drug-resistant intestinal cancer cell line is generally low. The miR-196b-5p is subjected to an overexpression or knockout experiment, which proves that the miR-196b-5p can effectively influence the sensitivity of intestinal cancer cells to cetuximab. The miR-196b-5p is expected to become a novel biomarker for early prediction and screening of drug resistance of colorectal cancer patients using cetuximab, and assists in dynamic monitoring of curative effect and overcoming of drug resistance.

The present invention discloses a method for degrading toxic and harmful substances in the bottom mud of channel catfish breeding ponds and inhibiting the proliferation of pathogenic bacteria in the bottom mud. It belongs to the field of breeding technology. The whole breeding process adopts the technology of precise feeding of biological fermented feed and the technology of replacing antibiotics with inulin, which complement each other. The core is to build a "double-effect" relationship of "probiotics-prebiotics". After use, it can significantly degrade organic matter in the bottom mud, greatly reduce the production of toxic and harmful products such as ammonia nitrogen and the proliferation of pathogenic bacteria such as Proteobacteria. When the above-mentioned technologies are used alone, the effects are not as significant as when they are used simultaneously. At the same time, after tracking for two consecutive breeding cycles, it was found that the output and specifications of channel catfish were significantly improved, and the breeding benefits of fishermen increased significantly.

The invention discloses an application of KIF4B as a biomarker for predicting prognosis of a lung cancer patient, relates to the technical field of biomedicine, and particularly relates to an application of KIF4B as a biomarker in preparation of NSCLC for prognosis and treatment. The research finds that the KIF4B gene is obviously and highly expressed in the NSCLC, and the expression of the KIF4B gene has obvious correlation with the prognosis, pathological grading, TN staging, invasion and infiltration and tumor size of the NSCLC; fluorescence multiple immunohistochemistry shows that the expression of the gene is in significant positive correlation with the expression of A549 and NCI-H1299 human NSCLC cell lines; the expression of the KIF4B gene is regulated in a targeted manner by using specific shRNA, and the expression level of the KIF4B gene is reduced, so that the proliferation and migration capabilities of NSCLC cells are greatly reduced, which indicates that the expression of the KIF4B gene is crucial to the NSCLC cells. The invention proves that the expression of the KIF4B gene is closely related to NSCLC cells, provides a new target source for prevention, diagnosis, detection and research of NSCLC, and provides a new drug preparation idea and clinical application prospect for NSCLC treatment.

The invention relates to an IL-2 mutant protein and application thereof. The invention specifically provides an IL-2 mutant protein. Compared with an IL-2 wild type, the mutant protein at least comprises one mutation site. The mutation can regulate the affinity between IL-2 and IL-2R alpha or IL-2R beta gamma, so as to regulate the activation of immune cells.

The invention discloses a long-chain non-coding RNA (Ribonucleic Acid) Link-NSC, shRNA (Short Hairpin Ribonucleic Acid) for interfering the expression of the Link-NSC, and application of an interference vector containing the Link-NSC in neural stem cell differentiation. The Link-NSC provided by the invention can be used for remarkably promoting the differentiation of neural stem cells, inducing cell apoptosis and reducing cell proliferation; the Link-NSC expression is knocked down under the in-vitro condition, proliferation of the neural stem cells can be promoted, differentiation and apoptosis of the neural stem cells can be inhibited, and a new means is provided for patients needing stem cell transplantation treatment.

The invention provides lactobacillus rhamnosus fermentation liquor for inhibiting proliferation of human norovirus and protein which is synthesized through a chemical path or genetic engineering and has a human norovirus adsorption effect. The preparation method of the fermentation liquor comprises the following steps: activating a lactobacillus rhamnosus YQ001 strain on a culture medium, standing and culturing at 37 DEG C for 24 hours, inoculating to a liquid culture medium, and standing and culturing at 37 DEG C; the protein (C2JVE6, C2JX39, C2K0J4) is a functional domain capable of binding to a capsid protein of a virus capable of causing diarrhea, and the virus capable of causing diarrhea comprises a human norovirus (HuNoVs). The fermentation liquor is applied to food additives, environment disinfectants and protection products. After the HuNoVs are treated by using the fermentation liquid supernatant, the replication level of the virus in the zebra fish body is obviously reduced, and an inhibition effect is shown.

The present invention relates to a whitening composition and a preparation method and application thereof, belonging to the technical field of whitening products. The composition of the present invention contains tea extract, raspberry ketone glucoside, ascorbic acid derivatives, nicotinamide, tranexamic acid, hydroxyethylpiperazine ethane sulfonic acid, twisted prickly cactus stem extract, and saxifrage extract; the tea extract, twisted prickly cactus stem extract, and saxifrage extract are products below 2kDa obtained by step-by-step enzymolysis of specific enzymes. Based on the problem that existing whitening products generally have only a single pathway and poor whitening effect, the present invention combines a variety of whitening active raw materials, combines a variety of whitening pathways with different action mechanisms, and exerts a synergistic effect, better solves skin pigmentation problems caused by various factors, and is safe and efficient.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating lung cancer and a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following raw material medicines: lily, radix ophiopogonis, thunberg fritillary bulb, astragalus membranaceus, curcuma zedoary, lychee seed, poria cocos, radix scrophulariae, rhizoma anemarrhenae and loofah sponge. The traditional Chinese medicine composition has the effects of tonifying qi and yin, reducing phlegm and resolving masses, and is particularly suitable for treating a patient suffering from qi-yin deficiency and blood stasis type small cell lung cancer. The traditional Chinese medicine composition disclosed by the invention has the effects of reducing tumor cell proliferation, regulating tumor immunity, reducing toxicity and enhancing efficacy, and can also enhance the immunity of a patient, prolong the lifetime of the patient and improve the living quality of the patient.

This invention relates to the field of biomedical technology, specifically to a micromolecule RNA-19b-3p and its application in the treatment of pancreatic ductal adenocarcinoma. The micromolecule RNA-19b-3p has the nucleotide sequence shown in SEQ ID NO:1. This invention discloses its use in the preparation of a medicament for treating pancreatic ductal adenocarcinoma, achieved by inhibiting the expression and / or activity of the micromolecule RNA-19b-3p. The medicament comprises a substance capable of reducing the expression or activity of the micromolecule RNA-19b-3p. This substance is its inhibitor, suppressor, antagonist, or antisense oligonucleotide. The medicament is used to inhibit the proliferation, migration, and / or invasion of pancreatic ductal adenocarcinoma cells. This invention provides a novel biomarker and therapeutic intervention target for pancreatic ductal adenocarcinoma, clarifies the feasibility of targeted therapy, and possesses clear translational potential.

This invention relates to the field of biomedical technology, specifically to a micromolecule RNA-191-5p and its application in the treatment of pancreatic ductal adenocarcinoma. The micromolecule RNA-191-5p has the nucleotide sequence shown in SEQ ID NO:1. This invention discloses its use in the preparation of a medicament for treating pancreatic ductal adenocarcinoma, achieved by inhibiting the expression and / or activity of the micromolecule RNA-191-5p. The medicament comprises a substance capable of reducing the expression or activity of the micromolecule RNA-191-5p. This substance is its inhibitor, suppressor, antagonist, or antisense oligonucleotide. The medicament is used to inhibit the proliferation, migration, and / or invasion of pancreatic ductal adenocarcinoma cells. This invention provides a novel biomarker and therapeutic intervention target for pancreatic ductal adenocarcinoma, clarifies the feasibility of targeted therapy, and possesses clear translational potential.

The present invention relates to an aptamer that specifically binds to cancer stem cells. The aptamer according to the present invention specifically binds to cancer stem cells, reduces cell adhesion, cell proliferation, anticancer drug resistance and cell migration that are characteristics of cancer stem cells, and has an excellent anticancer effect. Therefore, the aptamer can be used in the fields of cancer diagnosis, prognosis prediction and treatment in various ways.

The present invention belongs to the field of gene diagnosis and treatment, and specifically relates to the application of OLFM3 as a drug target for neuroblastoma. The present invention provides a reagent for inhibiting the expression of OLFM3 gene in the preparation of a therapeutic agent. MYCN The invention discloses that OLFM3 is involved in the treatment of neuroblastoma. MYCN Amplified neuroblastoma cells specifically expressed MYCN Very low expression in non-amplified neuroblastoma cells; MYCN In amplified neuroblastoma cells, knockdown of OLFM3 attenuated the proliferation and clone formation ability of neuroblastoma cells. OLFM3 promotes MYCN Amplification of malignant proliferation of neuroblastoma cells is MYCN Amplification of a new driver gene for malignant proliferation of neuroblastoma cells suggests that it is MYCN Amplification of novel therapeutic targets for neuroblastoma.